Unknown

Dataset Information

0

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.


ABSTRACT: OBJECTIVES:To assess the impact of exposure to single-dose nevirapine (sdNVP) on virological response in young Ugandan/Zimbabwean children (<3 years) initiating antiretroviral therapy (ART), and to investigate other predictors of response. DESIGN:Observational analysis within the ARROW randomized trial. METHODS:sdNVP exposure was ascertained by the caregiver's self-report when the child initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART. Viral load was assayed retrospectively over a median 4.1 years of follow-up. Multivariable logistic regression models were used to identify independent predictors of viral load below 80?copies/ml, 48 and 144 weeks after ART initiation (backwards elimination, exit P?=?0.1). RESULTS:Median (IQR) age at ART initiation was 17 (10-23) months in 78 sdNVP-exposed children vs. 21 (14-27) months in 289 non-exposed children (36 vs. 20% <12 months). At week 48, 49 of 73 (67%) sdNVP-exposed and 154 of 272 (57%) non-exposed children had viral load below 80?copies/ml [adjusted odds ratio (aOR) 2.34 (1.26-4.34), P?=?0.007]; 79 and 77% had viral load below 400 copies/ml. Suppression was significantly lower in males (P?=?0.009), those with higher pre-ART viral load (P?=?0.001), taking syrups (P?=?0.05) and with lower self-reported adherence (P?=?0.04). At week 144, 55 of 73 (75%) exposed and 188 of 272 (69%) non-exposed children had less than 80?copies/ml [aOR 1.75 (0.93-3.29), P?=?0.08]. There was no difference between children with and without previous sdNVP exposure in intermediate/high-level resistance to NRTIs (P?>?0.3) or NNRTIs (P?>?0.1) (n?=?88) at week 144. CONCLUSION:Given the limited global availability of lopinavir/ritonavir, its significant formulation challenges in young children, and the significant paediatric treatment gap, tablet fixed-dose-combination NVP-based ART remains a good alternative to syrup lopinavir-based ART for children, particularly those over 1 year and even if exposed to sdNVP.

SUBMITTER: Musoke P 

PROVIDER: S-EPMC4833198 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.

Musoke Philippa P   Szubert Alexander J AJ   Musiime Victor V   Nathoo Kusum K   Nahirya-Ntege Patricia P   Mutasa Kuda K   Williams David Eram DE   Prendergast Andrew J AJ   Spyer Moira M   Walker A Sarah AS   Gibb Diana M DM  

AIDS (London, England) 20150801 13


<h4>Objectives</h4>To assess the impact of exposure to single-dose nevirapine (sdNVP) on virological response in young Ugandan/Zimbabwean children (<3 years) initiating antiretroviral therapy (ART), and to investigate other predictors of response.<h4>Design</h4>Observational analysis within the ARROW randomized trial.<h4>Methods</h4>sdNVP exposure was ascertained by the caregiver's self-report when the child initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART. Viral load w  ...[more]

Similar Datasets

| S-EPMC2994321 | biostudies-literature
| S-EPMC3021781 | biostudies-literature